Searched for
OXFORD ASTRAZENECA PLC
Oxford Covid-19 vaccine tech maker Vaccitech targets $613 mn valuation in US IPOThe company, which has development programs for conditions including hepatitis B, prostate cancer and non-small cell lung cancer, has raise...- Australia to continue AstraZeneca vaccination despite blood clotting caseA 44-year-old man was admitted to a Melbourne hospital with clotting, days after receiving the AstraZeneca vaccine, suffering serious throm...
- Covid vaccine: Why is AstraZeneca making so many unforced errors?The has been communication of scientific results. November data from trials in the U.K. and Brazil generated confusion over efficacy. This ...
- US health agency questions robustness of AstraZeneca's COVID-19 vaccine trial dataThe Data and Safety Monitoring Board has notified the drugmaker, NIAID and the Biomedical Advanced Research and Development Authority regar...
- US authorization of AstraZeneca vaccine could come in April: OfficialCollins estimates that the FDA would need about three weeks to analyze the trial data, after which an expert advisory panel will meet and v...
- Brazil gives final approval for AstraZeneca vaccine, sees domestic manufactureThe AstraZeneca vaccine is already being administered in Brazil, but is registered only for emergency use, and the doses have been imported...
- Oxford study indicates AstraZeneca effective against Brazil variant, source saysThe data indicates that the vaccine will not need to be modified in order to protect against the variant, which is believed to have origina...
- AstraZeneca has sold its stake in Moderna for more than $1 billion: The TimesAstraZeneca is retaining partnership with Moderna on other disease treatments and could sell its AstraZeneca/Oxford University COVID-19 vac...
- Astra-Oxford shot is key to escaping pandemic for many nations, including IndiaThe AstraZeneca vaccine costs a fraction of the price set by Pfizer and will be manufactured in multiple countries, from India to Brazil. I...
- AstraZeneca's cancer drug fails to meet main goal in COVID-19 trialsThe drugmaker called the results from the study disappointing but said it remained committed to its clinical trials for its COVID-19 vaccin...
- Oxford COVID-19 vaccine produces immune response among elderly and young, AstraZeneca saysA vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people,...
- Inhaled vaccines aim to fight Coronavirus at its point of attackMost vaccines in human testing require two shots for effectiveness, and developers still aren’t even sure if they’ll prevent infections. Sc...
- India's Serum Institute starts manufacturing Codagenix's potential COVID-19 vaccineSerum Institute, the world's largest vaccine maker by the number of doses produced, will develop Codagenix's CDX-005, which is delivered in...
- AstraZeneca Pharma surges 13% as parent resumes phase 3 vaccine trials in UKThe Serum Institute of India said it would restart its trials once it had permission from the Drugs Controller General of India, Reuters re...
- Pause in AstraZeneca vaccine trial not necessarily a setback, says UK health ministerAstraZeneca Plc said it had paused global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unex...
- European shares rise; AstraZeneca drops after halting vaccine trialsThe pan-European STOXX 600 index rose 0.8%, with sub-indexes of sectors hit most by the pandemic lagging. Travel and leisure stocks fell 1....
- AstraZeneca plunges 13% as Covid-19 drug trial put on holdAstraZeneca began its Phase 3 trial in the US in late August. The US trial was currently taking place at 62 sites across the country.
- AstraZeneca in first COVID-19 vaccine deal with Chinese companyThe deal underscores Astra's frontrunner position in a global race to deliver an effective vaccine, given that Chinese ventures are leading...
- Oxford coronavirus vaccine prompts immune response in early testScientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune r...
- AstraZeneca approaches Gilead about potential mergerAstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger.
Load More
